RigosertibPI3K/PLK1 inhibitor CAS# 592542-59-1 |
- Ro3280
Catalog No.:BCC3962
CAS No.:1062243-51-9
- MLN0905
Catalog No.:BCC3961
CAS No.:1228960-69-7
- Rigosertib
Catalog No.:BCC4296
CAS No.:592542-59-1
- Rigosertib sodium
Catalog No.:BCC4067
CAS No.:592542-60-4
- GW843682X
Catalog No.:BCC1614
CAS No.:660868-91-7
- GSK461364
Catalog No.:BCC3788
CAS No.:929095-18-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 592542-59-1 | SDF | Download SDF |
PubChem ID | 6918736 | Appearance | Powder |
Formula | C21H25NO8S | M.Wt | 451.49 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | ON-01910 | ||
Solubility | DMSO : 75 mg/mL (166.12 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | 2-[2-methoxy-5-[[(E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]anilino]acetic acid | ||
SMILES | COC1=C(C=C(C=C1)CS(=O)(=O)C=CC2=C(C=C(C=C2OC)OC)OC)NCC(=O)O | ||
Standard InChIKey | OWBFCJROIKNMGD-BQYQJAHWSA-N | ||
Standard InChI | InChI=1S/C21H25NO8S/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24/h5-11,22H,12-13H2,1-4H3,(H,23,24)/b8-7+ | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Rigosertib is a non-ATP-competitive inhibitor of PLK1 with an IC50 of 9 nM, and shows 30-fold greater selectivity against PLK2.In Vitro:Rigosertib is non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM. Rigosertib also exhibits inhibition of PLK2, PDGFR, Flt1, BCR-ABL, Fyn, Src, and CDK1, with IC50 of 18-260 nM. Rigosertib shows cell killing activity against 94 different tumor cell lines with IC50 of 50-250 nM, including BT27, MCF-7, DU145, PC3, U87, A549, H187, RF1, HCT15, SW480, and KB cells. While in normal cells, such as HFL, PrEC, HMEC, and HUVEC, Rigosertib has little or no effect unless its concentration is greater than 5-10 μM. In HeLa cells, Rigosertib (100-250 nM) induces spindle abnormalities and apoptosis[1]. Rigosertib also inhibits several multidrug resistant tumor cell lines, including MES-SA, MES-SA/DX5a, CEM, and CEM/C2a, with IC50 of 50-100 nM. In DU145 cells, Rigosertib (0.25-5 μM) blocks cell cycle progression in G2/M phase, results in an accumulation of cells containing subG1 content of DNA, and activates apoptotic pathways. In A549 cells, Rigosertib (50 nM-0.5 μM) induces loss of viability and caspase 3/7 activation[2]. Rigosertib sodium (2 μM) induces apoptosis in chronic lymphocytic leukemia (CLL) cells without toxicity against T-cells or normal B-cells. Rigosertib sodium (2 μM) also abrogates the pro-survival effect of follicular dendritic cells on CLL cells and reduces SDF-1-induced migration of leukemic cells[3].In Vivo:Rigosertib (250 mg/kg, i.p.) markedly inhibits tumor growth in mouse xenograft models of Bel-7402, MCF-7, and MIA-PaCa cells[1]. Rigosertib (200 mg/kg, i.p.) shows inhibition on tumor growth in a mouse xengraft model of BT20 cells[2]. References: |
Rigosertib Dilution Calculator
Rigosertib Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.2149 mL | 11.0744 mL | 22.1489 mL | 44.2978 mL | 55.3722 mL |
5 mM | 0.443 mL | 2.2149 mL | 4.4298 mL | 8.8596 mL | 11.0744 mL |
10 mM | 0.2215 mL | 1.1074 mL | 2.2149 mL | 4.4298 mL | 5.5372 mL |
50 mM | 0.0443 mL | 0.2215 mL | 0.443 mL | 0.886 mL | 1.1074 mL |
100 mM | 0.0221 mL | 0.1107 mL | 0.2215 mL | 0.443 mL | 0.5537 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Rigosertib is a dual inhibitor of phosphoinositide 3-kinase (PI3K) and polo-like kinase 1 (PLK1) [1].
In vitro studies show that rigosertib inhibits the PI3K/AKT pathway, down-regulates cyclin D1, induces NOXA and BIM and activates the JNK pathway in human leukemic cells. Rigosertib induces apoptosis of a variety of human tumor cell lines including breast, prostate, ovarian, pancreatic, SCLC, colorectal, melanoma and et al. For instant, it shows anti-tumor efficacy in BT20, MCF-7, BT474, OV-CAR-3, A549 and HCT-116 with IC50 values of 80nM, 75nM, 50nM, 75nM, 90nM and 75nM, respectively. In addition, rigosertib is also effective against the drug resistant tumor cell lines. It potently inhibits tumor growth with IC50 values of 100nM and 50nM against MES-SA/DX5 and CEM/C2, respectively. Moreover, it is reported that rigosertib can affect the cell cycle of both normal cells and tumor cells. Rigosertib leads to a blockade of cell cycle progression in the G1 and G2/M phases in normal diploid human fetal lung cells. When treated with DU145 cells, rigosertib induces cell cycle arrest in G2/M phase [2].
References:
[1] Anderson R T, Keysar S B, Bowles D W, et al. The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas. Molecular cancer therapeutics, 2013, 12(10): 1994-2005.
[2] Reddy M V R, Venkatapuram P, Mallireddigari M R, et al. Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-Methoxy-5-[(2′, 4′, 6′-trimethoxystyrylsulfonyl) methyl] phenylamino} acetate (ON 01910. Na): synthesis, structure–activity relationship, and biological activity. Journal of medicinal chemistry, 2011, 54(18): 6254-6276.
- Chikusetsu Saponin Ib
Catalog No.:BCC8308
CAS No.:59252-87-8
- Laurocapram
Catalog No.:BCN8308
CAS No.:59227-89-3
- Erigeroside
Catalog No.:BCC8171
CAS No.:59219-76-0
- Darutoside
Catalog No.:BCN4094
CAS No.:59219-65-7
- 8(14),15-Isopimaradiene-3,18-diol
Catalog No.:BCN4093
CAS No.:59219-64-6
- beta-Dihydroplumericinic acid
Catalog No.:BCN4092
CAS No.:59204-61-4
- Sulforaphene
Catalog No.:BCN8179
CAS No.:592-95-0
- PSB 10 hydrochloride
Catalog No.:BCC7238
CAS No.:591771-91-4
- Neoisoliquiritin
Catalog No.:BCN2936
CAS No.:59122-93-9
- Misoprostol
Catalog No.:BCC5240
CAS No.:59122-46-2
- Alpha-Angelica lactone
Catalog No.:BCN5001
CAS No.:591-12-8
- (+)-Rhododendrol
Catalog No.:BCN7091
CAS No.:59092-94-3
- Rigosertib sodium
Catalog No.:BCC4067
CAS No.:592542-60-4
- Meptazinol HCl
Catalog No.:BCC4920
CAS No.:59263-76-2
- Acyclovir
Catalog No.:BCC3929
CAS No.:59277-89-3
- Decursin
Catalog No.:BCN5335
CAS No.:5928-25-6
- Sissotrin
Catalog No.:BCN4095
CAS No.:5928-26-7
- Vitexin 2''-O-p-coumarate
Catalog No.:BCN2793
CAS No.:59282-55-2
- Lindleyin
Catalog No.:BCN8450
CAS No.:59282-56-3
- Triacontanol
Catalog No.:BCC8260
CAS No.:593-50-0
- Alizapride HCl
Catalog No.:BCC4618
CAS No.:59338-87-3
- PIK-93
Catalog No.:BCC2519
CAS No.:593960-11-3
- Darutigenol
Catalog No.:BCN4096
CAS No.:5940-00-1
- Boc-HoSer(Bzl)-OH
Catalog No.:BCC3244
CAS No.:59408-74-1
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.[Pubmed:27400247]
Expert Rev Anticancer Ther. 2016 Aug;16(8):805-10.
INTRODUCTION: Hypomethylating agents (HMAs) are the standard of care for patients with higher-risk myelodysplastic syndromes (MDS), but patients who relapse or are refractory have a poor prognosis with an estimated survival of 4-6 months. Rigosertib, a Ras mimetic that inhibits the phophoinositide 3-kinase and polo-like kinase pathways, has been tested in patients with higher-risk MDS following treatment with HMAs, where there are no approved second-line therapies. AREAS COVERED: This review will provide an overview of Rigosertib, including safety and efficacy demonstrated in clinical trials. Expert commentary: There is an urgent need for new treatment options for patients who have failed or progressed on HMAs. Rigosertib is currently undergoing testing as a single agent in certain subsets of higher-risk MDS patients as well as in combination with azacitidine, where preliminary data show efficacy in patients with de novo MDS as well as HMA failures.
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.[Pubmed:26968357]
Lancet Oncol. 2016 Apr;17(4):496-508.
BACKGROUND: Hypomethylating drugs are the standard treatment for patients with high-risk myelodysplastic syndromes. Survival is poor after failure of these drugs; there is no approved second-line therapy. We compared the overall survival of patients receiving Rigosertib and best supportive care with that of patients receiving best supportive care only in patients with myelodysplastic syndromes with excess blasts after failure of azacitidine or decitabine treatment. METHODS: We did this randomised controlled trial at 74 hospitals and university medical centres in the USA and Europe. We enrolled patients with diagnosis of refractory anaemia with excess blasts (RAEB)-1, RAEB-2, RAEB-t, or chronic myelomonocytic leukaemia based on local site assessment, and treatment failure with a hypomethylating drug in the past 2 years. Patients were randomly assigned (2:1) to receive Rigosertib 1800 mg per 24 h via 72-h continuous intravenous infusion administered every other week or best supportive care with or without low-dose cytarabine. Randomisation was stratified by pretreatment bone marrow blast percentage. Neither patients nor investigators were masked to treatment assignment. The primary outcome was overall survival in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT01241500. FINDINGS: From Dec 13, 2010, to Aug 15, 2013, we enrolled 299 patients: 199 assigned to Rigosertib, 100 assigned to best supportive care. Median follow-up was 19.5 months (IQR 11.9-27.3). As of Feb 1, 2014, median overall survival was 8.2 months (95% CI 6.1-10.1) in the Rigosertib group and 5.9 months (4.1-9.3) in the best supportive care group (hazard ratio 0.87, 95% CI 0.67-1.14; p=0.33). The most common grade 3 or higher adverse events were anaemia (34 [18%] of 184 patients in the Rigosertib group vs seven [8%] of 91 patients in the best supportive care group), thrombocytopenia (35 [19%] vs six [7%]), neutropenia (31 [17%] vs seven [8%]), febrile neutropenia (22 [12%] vs ten [11%]), and pneumonia (22 [12%] vs ten [11%]). 41 (22%) of 184 patients in the Rigosertib group and 30 (33%) of 91 patients in the best supportive care group died due to adverse events and three deaths were attributed to Rigosertib treatment. INTERPRETATION: Rigosertib did not significantly improve overall survival compared with best supportive care. A randomised phase 3 trial of Rigosertib (NCT 02562443) is underway in specific subgroups of patients deemed to be at high risk, including patients with very high risk per the Revised International Prognostic Scoring System criteria. FUNDING: Onconova Therapeutics, Leukemia & Lymphoma Society.
ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.[Pubmed:27764820]
Oncotarget. 2016 Nov 29;7(48):79388-79400.
Squamous cell carcinoma of the head and neck (HNSCC) is characterized by high morbidity and mortality. Treatment failure, drug resistance and chemoradiation toxicity have necessitated the development of alternative treatment strategies. Styryl benzyl sulfones, a family of novel small molecule inhibitors, are being evaluated as anti-neoplastic agents in multiple clinical trials. The activity of these compounds has been well characterized in several preclinical tumor studies, but their activity has yet to be fully examined in HNSCC. We tested ON 01910.Na (Rigosertib), a styryl benzyl sulfone in late-stage development, in HNSCC preclinical models. Rigosertib induced cytotoxicity in both HPV(+) and HPV(-) HNSCC cells in a dose-dependent manner. Characterization of the underlying molecular mechanism indicated that Rigosertib induced inhibition of the PI3K/Akt/mTOR pathway, induced oxidative stress resulting in increased generation of reactive oxygen species (ROS), and activated extracellular signal-regulated kinases (ERK1/2) and c-Jun NH2-terminal kinase (JNK). Increased phosphorylation and cytoplasmic translocation of ATF-2 were also observed following Rigosertib treatment. These changes in cell signaling led us to consider combining Rigosertib with HNSCC standard-of-care therapies, such as cisplatin and radiation. Our study highlights the promising preclinical activity of Rigosertib in HNSCC irrespective of HPV status and provides a molecular basis for Rigosertib in combination with standard of care agents for HNSCC.